Files Preliminary Schedule 14c Filing To Officially Issue Dividend Payouts For Previous And Current Shareholders [Market News Publishing (US)] CANNABIS SCIENCE INC
CANNABIS SCIENCE INC ("CBIS-0") - Files Preliminary Schedule 14c Filing To Officially Issue - Dividend Payouts For Previous And Current Shareholders
Cannabis Science Inc., a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce it has filed its preliminary Schedule 14C filing as the next steps to complete its dividend payout of the previously filed dividend share payout as filed with the S.E.C. on a Definitive Schedule 14C on August 18, 2011 and include all shareholders in on what the Company considers a landmark growth curve.
The Company has met the initial target of filing the preliminary statement with the new structure program by the end of August 2015 with no reverse split, with the main focus on increasing shareholder value for everyone involved. As planned the Company will apply for a unique trading symbol to accommodate a $15 - 25 million USD range financing it has been actively negotiating to accelerate all its drug development programs and expand its State-by-State initiatives. Once the financing has been successfully negotiated and closed the Company will formally pursue the contemplated up listing to NASDAQ.
(1) To issue a new dividend to holders of our current common stock so they received 1 share of Class A common stock and 1 non-transferable share purchase warrant for each 100 shares of our current class of common stock that they previously owned as of the record date, October 9, 2015. Each warrant will grant the holder to purchase an additional share of Class A common stock at a price of $1.00 per share. The warrant will be exercisable for 90 days from the date that the Class A common stock receives a trading symbol.
(2) To issue the previously announced and approved dividend that will issue 1 share of Class A common stock and 1 non-transferable share purchase warrant for each 10 shares of the Company's current common stock that they previously owned as of the record date of December 31, 2010. Each warrant will grant the holder to purchase an additional share of Class A common stock at a price of $1.00 per share. The warrant will be exercisable for 90 days from the date that the Class A common stock receives a trading symbol.
"All our shareholders can rest assured that once we have the required regulatory approvals we will publicly inform everyone with the same information on how to retrieve their dividend share payout on a timely basis. It will most likely be done through the transfer agent communicating with each shareholder directly to confirm share ownership dates. We are excited to give our all shareholders their dividend payout, close out these financing deals, and begin our quest for NASDAQ. Again, it's been a long and very exciting road, with all the opportunities we have collected along the way. We certainly believe this dividend structure gives our previous and current shareholders of record an outstanding opportunity to capitalize on the share dividend payout to create another asset base for them, while the company utilizes the new class of Common A shares with a higher value to complete our negotiations for a much larger funding to push our drug development programs forward much faster," stated Mr. Raymond C. Dabney, Director, President & CEO, Co-Founder, Cannabis Science, Inc.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.
Cannabis Science, Inc. Mr. Raymond C. Dabney Director, President & CEO, Co-Founder raymond.dabney@cannabisscience.com Direct: 1.310.650.3788
Cannabis Science, Inc. Mr. Robert Kane Director & CFO info@cannabisscience.com Tel: 1.888.889.0888
Cannabis Science, Inc. Mr. Derwin A. Wallace Finance & Investor Relations info@cannabisscience.com Tel: 1.888.889.0888
______________________________________
_______________________________________________
OTCBB closing price for CBIS-0 Date: 2015/09/02 Closing Price: 0.04
Cannabis Science to Issue Dividend Payouts for Previous and Current Shareholders, a $15-25 Million Capital Raise for FDA and Other Clinical Drug Development Programs as Well as a Proposed NASDAQ Up Listing COLORADO SPRINGS, CO -- (Marketwired) -- 08/18/15 -- Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce the closure and issuance of the previously filed dividend share payout as filed with the S.E.C. on a Definitive Schedule 14C on August 18, 2011, the Definitive Schedule 14C filing (RULE 14c-101). The Company also intends to file another Information Statement to accommodate new shareholders to date to receive a similar dividend payout, to bring all shareholders in on what the Company considers a landmark growth curve. The Company expects to accelerate its current FDA targeted drug development programs and expand its State-by-State initiatives. Increasing shareholder value is of foremost importance for everyone involved; to this end the Company will apply for a unique trading symbol to accommodate a $15 - 25 million USD range financing it has been actively negotiating for the newly created class of dividend payout Common A stock, and formally pursue a contemplated up listing to NASDAQ. The Company expects to begin filing the complete new structure program with no reverse split by the end of the month.
Cannabis Science, Inc. (the "Company") wishes to update its current and former shareholders regarding the previously approved share dividend, which was filed on a Definitive Schedule 14C with the Commission on August 18, 2011. The Company will use its best efforts to issue the share dividend, which is one new share of Class A common stock for each ten shares of common stock that they owned as of December 31, 2010. In addition to this dividend, the Company intends to file a new Information Statement pursuant to Section 14(C) to issue a new dividend to shareholders as of October 9, 2015. The Company intends to seek the approval to issue a dividend of one share of Class A common stock for each one hundred shares owned by shareholders of record as of October 9, 2015. Both dividends will also carry a warrant that will give each shareholder of record a share purchase warrant consisting of an option to purchase one additional share of Class A common stock for each special dividend share received. Each warrant will be exercisable into one share of Class A stock at a price of $1.00 per share for a period of three months after all the proposed changes officially take effect. The Company also plans to apply for a unique and separate trading symbol for its shares of Class A common stock.
"We are very excited to give our all shareholders a dividend payout and get on with the business at hand. It's been a long and very exciting road, with lots of opportunities we have collected along the way. We believe this dividend structure gives our previous and current shareholders of record an outstanding opportunity to capitalize on the share dividend payout to create another asset base for them, while the company utilizes the new class of Common A shares with a higher value to complete our negotiations for a much larger funding to push our drug development programs forward much faster. As regulation changes swiftly in such an enormous burgeoning industry, it creates opportunities and it can create hurdles for those same opportunities. We must remain fluid and move as the regulations move. We believe our team of Scientific Advisors gives us the unique opportunity to strive for excellence in our drug development programs as their track record speaks volumes for themselves. Our expansion program will be fueled by the growing market and demand," stated Mr. Raymond C. Dabney, President & CEO, Co-Founder, Cannabis Science Inc.
About Cannabis Science, Inc. Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc. Mr. Raymond C. Dabney President & CEO, Co-Founder raymond@cannabisscience.com Tel: 1.888.889.0888 Direct: 1.310.650.3788
Mr. Robert Kane Director & CFO info@cannabisscience.com Tel: 1.888.889.0888
Mr. Derwin A. Wallace Finance & Investor Relations info@cannabisscience.com Tel: 1.888.889.0888 Direct: 1.404.500.4950
News 
Market Data 
Discover 
